Faeth Therapeutics Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Faeth Therapeutics is a small to mid-sized biotechnology company based in San Francisco, California, focused on cancer metabolism. It develops therapies intended to interfere with the metabolic pathways that support tumor growth, seeking to broaden options for cancer treatment. Positioned within the biotechnology research sector, the company translates metabolic biology into clinical-stage cancer therapies. Faeth has advanced a Phase 2 trial in endometrial cancer in collaboration with the Gynecologic Oncology Group and has reported results from a Phase 2 study in ovarian cancer presented at the ESMO Congress in 2025. The organization participates in major oncology forums to share findings related to metabolism-targeted cancer strategies. In February 2026, Faeth Therapeutics was acquired by Sensei Bio, Inc. in an all-stock transaction.